Speakers

Partner at Invivo Partners, she joined the firm in January 2018. Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. The firm recently announced its third fund, targeting €100 million for investments in early-stage life science companies, with a particular focus on advanced therapies.

She serves as a Member of the Board of Directors at OneChain, Telomere Therapeutics, Esobiotec and SIgnadori Bio, and as an Observer at Arthex, Pulmobiotics, Gyala Therapeutics, and Telum.

Previously, she worked as a Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.

She has five years of R&D experience in oncology and gene therapy, which has led to publications in peer-reviewed journals and collaborations with biotechnology companies.

She holds a BSc in Biotechnology from the Autonomous University of Barcelona (UAB), a PhD in Biotechnology from the University of Barcelona (UB), and has completed a postgraduate course in Innovation Management at UAB.